Wan Renhong, Song Ruiwen, Fan Yihua, Li Linhui, Zhang Jiangxin, Zhang Beijia, Li Xinju, Wang Shenjun
Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China.
Evid Based Complement Alternat Med. 2021 Aug 19;2021:7604537. doi: 10.1155/2021/7604537. eCollection 2021.
Chaihu Jia Longgu Muli decoction (CLMD) is widely used in the treatment of poststroke depression (PSD) in China. Some evidences show that it has advantages, but there lacks reliable evidence. This study aims to systematically evaluate the efficacy and safety of CLMD in the treatment of PSD.
All randomized controlled trials (RCTs) of CLMD in the treatment of PSD were searched from the following databases: PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Database, VIP Database, and Chinese Biomedical Literature Service System (CBM), from their inception to May 2021. Two researchers independently screened the literature, extracted the data, and evaluated the risk of bias in the included studies. Meta-analysis was performed using RevMan5.3 software.
A total of 13 RCTs involving 1665 patients were finally included in this study, among which 5 RCTs were oral CLMD alone versus antidepressants, and 8 RCTs were oral CLMD with antidepressants versus antidepressants. Meta-analysis results showed that oral administration of CLMD could improve Hamilton's Depression Scale (HAMD) and the Modified Edinburgh-Scandinavian Stroke Scale (MESSS) scores, improve the Barthel index, and have a low rate of adverse reactions, but there was no significant difference in the total effective rate (=0.21 > 0.05) and the National Institute of Health Stroke Scale (NIHSS) score (=0.47 > 0.05) between the antidepressants group and the oral administration of the CLMD group. Oral CLMD combined with antidepressants could improve the total effective rate, HAMD, and MESSS score, but there was no significant difference in Barthel index (=0.06 > 0.05) and the adverse reaction rate (=0.14 > 0.05) between the two groups.
Current evidence suggests that oral CLMD alone or with antidepressants is more effective and safer in the treatment of PSD than oral antidepressants. Due to the limitation of the quality and quantity of the included studies, more high-quality studies are needed to confirm the above conclusion.
柴胡加龙骨牡蛎汤(CLMD)在中国广泛用于治疗脑卒中后抑郁(PSD)。一些证据表明其具有优势,但缺乏可靠证据。本研究旨在系统评价CLMD治疗PSD的疗效和安全性。
从以下数据库检索CLMD治疗PSD的所有随机对照试验(RCT):PubMed、Cochrane图书馆、Embase、Web of Science、中国知网(CNKI)、万方数据库、维普数据库和中国生物医学文献服务系统(CBM),检索时间从建库至2021年5月。两名研究人员独立筛选文献、提取数据并评估纳入研究的偏倚风险。使用RevMan5.3软件进行荟萃分析。
本研究最终纳入13项RCT,共1665例患者,其中5项RCT为单纯口服CLMD与抗抑郁药对比,8项RCT为口服CLMD联合抗抑郁药与抗抑郁药对比。荟萃分析结果显示,口服CLMD可改善汉密尔顿抑郁量表(HAMD)及改良爱丁堡斯堪的纳维亚卒中量表(MESSS)评分,提高Barthel指数,且不良反应发生率较低,但抗抑郁药组与口服CLMD组在总有效率(=0.21>0.05)及美国国立卫生研究院卒中量表(NIHSS)评分(=0.47>0.05)方面差异无统计学意义。口服CLMD联合抗抑郁药可提高总有效率、HAMD及MESSS评分,但两组在Barthel指数(=0.06>0.05)及不良反应发生率(=0.14>0.05)方面差异无统计学意义。
目前证据表明,单独口服CLMD或联合抗抑郁药治疗PSD比口服抗抑郁药更有效且更安全。由于纳入研究的质量和数量有限,需要更多高质量研究来证实上述结论。